Accretive vs Dilutive Acquisitions: How M&A Affects EPS

An acquisition is accretive if it increases the buyer’s earnings per share (EPS) after the deal closes, and dilutive if it decreases it. Accretion/dilution analysis is the quick test bankers and investors run on almost every merger announcement: combine the two companies’ earnings, account for how the deal was paid for, and see whether the buyer’s EPS goes up or down. It’s a useful first filter — but a deal can be accretive and still destroy value, or dilutive and still be smart.

Why EPS is the yardstick

Earnings per share is net income divided by shares outstanding. Public companies are often valued as a multiple of it — the P/E ratio — so a change in EPS, holding the multiple steady, implies a change in share price. Management teams know analysts will immediately ask whether a deal is accretive, and a dilutive deal can spook shareholders even when the strategic logic is sound.

The analysis boils down to comparing pro forma EPS (the combined company) with the buyer’s standalone EPS:

Pro forma EPS = (Buyer net income + Target net income
                 + after-tax synergies
                 - after-tax financing costs
                 - new amortization)
                / (Buyer shares + new shares issued)

If pro forma EPS is higher than standalone EPS, the deal is accretive. If lower, it’s dilutive.

How the payment method drives the answer

How the buyer pays is usually the biggest single factor.

Paying with stock. The buyer issues new shares to the target’s owners. The numerator grows by the target’s earnings, and the denominator grows by the new shares. A useful rule of thumb: an all-stock deal tends to be accretive when the buyer’s P/E is higher than the P/E it’s paying for the target. A highly valued buyer effectively uses its expensive “currency” to buy cheaper earnings. If the buyer’s P/E is lower than the price it’s paying, each new share brings in less earnings than an existing share already represents — dilutive. Issuing shares also creates equity dilution of ownership, separate from the EPS effect.

Paying with cash on hand. No new shares, but the buyer gives up the interest it was earning on that cash. If the target’s earnings yield (earnings divided by purchase price) is higher than the after-tax interest forgone, the deal is accretive.

Paying with debt. Again no new shares, but new after-tax interest expense comes out of the numerator. When borrowing costs are low relative to the target’s earnings yield, debt-financed deals look very accretive on paper — which is one reason leverage is popular in M&A.

A simplified example

Suppose the buyer earns $100 million on 100 million shares — EPS of $1.00 — and trades at a P/E of 20, so its shares cost $20.

It wants a target earning $20 million, at a purchase price of $300 million (a P/E of 15).

All-stock deal. At $20 per share, the buyer issues 15 million new shares.

• Combined earnings: $120 million
• Combined shares: 115 million
• Pro forma EPS: about $1.04 — accretive, because the buyer’s P/E (20) is above the price paid (15).

Same deal, but the buyer’s P/E is 12. Its shares now cost $12, so it must issue 25 million shares.

• Combined earnings: $120 million
• Combined shares: 125 million
• Pro forma EPS: $0.96 — dilutive.

Same target, same price — the outcome flipped purely because of the buyer’s valuation. (These figures ignore synergies, fees, financing costs, and amortization to keep the mechanics visible.)

Accretive vs dilutive at a glance

	Accretive deal	Dilutive deal
Effect on buyer EPS	Increases	Decreases
All-stock rule of thumb	Buyer P/E above target purchase P/E	Buyer P/E below target purchase P/E
Cash/debt rule of thumb	Target earnings yield above after-tax cost of funds	Target earnings yield below after-tax cost of funds
Typical market reaction	Easier to sell to shareholders	Needs a strong strategic case
Does it prove value creation?	No	No

The adjustments that change the math

Real accretion/dilution models include several items the simple version skips:

• Synergies. Cost savings or revenue gains from combining the businesses. Announced synergies can turn a dilutive deal accretive — and are also the most commonly overestimated number in the model.
• Purchase accounting and amortization. When the price exceeds the target’s book value, the excess is split between identifiable intangible assets, which are amortized and reduce earnings, and goodwill, which isn’t amortized under US GAAP but is tested for impairment. That’s why many companies report “adjusted” EPS that excludes deal-related amortization.
• Transaction and integration costs. Advisory fees, severance, and systems integration hit earnings in the first years.
• Foregone interest and new debt costs, as covered above.
• Timing. Deals are often described as “dilutive in year one, accretive by year two” once synergies ramp up and one-off costs roll off.

Why accretion doesn’t equal value creation

EPS accretion is an accounting outcome, not an economic one. A few reasons it can mislead:

• It ignores the cost of equity. Issuing shares or using cash has an opportunity cost that EPS doesn’t capture. A deal can lift EPS while earning a return below the buyer’s weighted average cost of capital, which destroys value.
• Leverage flatters it. Cheap debt makes almost any deal accretive, but adds risk that the market may price in with a lower P/E.
• The multiple can change. If the buyer acquires a slower-growing or lower-quality business, investors may assign the combined company a lower P/E, offsetting the higher EPS.
• It’s sensitive to inputs. Small changes to synergy or financing assumptions can flip the sign.

Analysts therefore pair accretion/dilution with other lenses: return on invested capital versus cost of capital, a DCF valuation of the target including synergies, and how much of the expected value the buyer is handing to the seller as a premium.

The takeaway

An acquisition is accretive if it raises the buyer’s EPS and dilutive if it lowers it. The financing mix drives most of the result: stock deals hinge on the buyer’s P/E versus the price paid, and cash or debt deals hinge on the target’s earnings yield versus the after-tax cost of funds. Treat accretion as a headline check, not a verdict — whether a deal creates value depends on the return it earns relative to its true cost of capital.